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Background: Tobramycin pharmacokinetics have not been evaluated previously in a large series of data collected in children and adults with
CF receiving once (OD) or three times daily (TD) tobramycin.
Methods: Therapeutic drug monitoring data in children and adults with CF who participated in a randomised clinical trial evaluating efficacy
and toxicity of OD versus TD tobramycin (TOPIC study) were analysed retrospectively. Population pharmacokinetic models stratified to
treatment schedule were created, and individual pharmacokinetic parameters were calculated.
Results: In paediatric patients, volume of distribution per kg body weight (V1) was greater with OD treatment compared to TD (0.401
±0.092 versus 0.354±0.041, p=0.003). Elimination rate was reduced in all patients receiving OD tobramycin compared to TD (children:
0.00197±0.00027 versus 0.00291±0.00041, pb0.001, adults: 0.00252±0.00008 versus 0.00322±0.00050, pb0.001). Tobramycin V1
decreased with increasing age (R2=0.3, pb0.001).
Conclusions: The reduced elimination rate in OD may either be caused by circadian pharmacokinetic behaviour of tobramycin or indicates
early renal damage caused by high tobramycin doses not detected by biochemical measurements. However, results of our previous work
suggest that OD tobramycin may be less nephrotoxic. The higher V1 in children implies that a relative higher tobramycin dose in these
patients is needed for the same target peak serum concentration.
© 2007 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reservedKeywords: Tobramycin; Pharmacokinetics; Diurnal variation1. Introduction
A cornerstone of the antimicrobial treatment of patients
with cystic fibrosis (CF) is the intravenous administration of
tobramycin [1]. Despite more than 50 years of experience
with aminoglycosides, there is still debate on the optimal
way to administer these drugs. Serious drawbacks for
aminoglycoside use are nephro- and ototoxicity. However,
aminoglycosides, particularly tobramycin, are highly active
against the most important cystic fibrosis pathogen, Pseu-
domonas aeruginosa, and so these drugs are likely to retain⁎ Corresponding author. Tel.: +31 70 3217180; fax: +31 70 3217156.
E-mail address: d.touw@ahz.nl (D.J. Touw).
1569-1993/$ - see front matter © 2007 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2006.12.007an important role in the management of pulmonary infection
in cystic fibrosis.
Since the introduction of aminoglycosides, initiatives
have been taken to optimise their management, thereby
increasing efficacy, minimising toxicity and reducing the
development of resistance. In vitro research has provided
evidence that once daily dosing (better named as extended
interval dosing) may be at least as effective and less toxic as
multiple daily dosing. In other diseases than CF, the use of
extended interval dosing is widespread and recently the
TOPIC study has added important clinical evidence to
support this approach in patients with CF [2]. Another
important initiative is the use of therapeutic drug monitoring
(TDM) aimed at early optimisation of serum levels toed by Elsevier B.V. All rights reserved
Table 2
Overview of tobramycin pharmacokinetic models built from the patients
participating in the TOPIC study
Parameter Mean±s.d.
Overall pharmacokinetic model (N=136)
V1 (l/kg) 0.335±0.055
Kelm (hr−1) 0.01⁎
Kelr (hr−1/(ml/min/1.73 m2)) 0.00294±0.00028
All paediatric patients (N=85)
V1 (l/kg) 0.363±0.081⁎⁎
Kelm (hr−1) 0.01⁎
Kelr (hr−1/(ml/min/1.73 m2)) 0.00281±0.00035
All adult patients (N=51)
V1 (l/kg) 0.294±0.038⁎⁎
Kelm 0.01⁎
Kelr (hr−1/(ml/min/1.73 m2)) 0.00314±0.00029
V1: volume of distribution per kg body weight; Kelm: metabolic elimination
rate; Kelr: renal elimination rate per ml/min/1.73 m2 creatinine clearance;
⁎: value fixed to 0.01 because of lack of data (for explanation: see text);
⁎⁎: significantly different ( pb0.001).
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early TDM may have beneficial effects on patients’ out-
comes and toxicity [3]. For optimal guidance of tobramycin
therapy in patients with CF, reliable population pharmaco-
kinetic models are necessary; on the one hand to develop
dosing schemes and on the other hand for TDM [4].
The TOPIC study is by far the largest study conducted in
CF where pharmacokinetic data have been obtained in a
structured way in adults and in children with cystic fibrosis.
The TOPIC study can be seen as 4 cohorts of patients;
children and adults receiving three times daily 3.3 mg/kg
tobramycin, and children and adults receiving once daily
10 mg/kg tobramycin. The purpose of this post-hoc analysis
was 1) to build pharmacokinetic models in children and in
adults for tobramycin either administered three times daily
3.3 mg/kg body weight or once daily 10 mg/kg body weight
to be utilised for TDM and dosage adjustment of tobramycin
in children and adults with cystic fibrosis and 2) to compare
these models with each other and with published data.
2. Materials and methods
2.1. Patients and treatment schedule
TOPIC study: Patients were enrolled from 21 cystic
fibrosis centres in the UK (15 paediatric and 6 adult
centres). The study was approved by Trent multicentre
research ethics committee and by local ethics committees in
all centres. Written informed consent was obtained from
adult patients and from parents of children under 18 years
(with the child or young person giving assent). All
participants had a diagnosis of cystic fibrosis (i.e., sweatTable 1
Overview of demographic characteristics and tobramycin levels of patients
participating in the TOPIC study [2] and where a pharmacokinetic analysis
could be carried out
Three times daily
tobramycin
Once daily
tobramycin
Paediatric patients (N) 43 42
Male/female 28/15 25/17
Age (years) 10.0±3.0 (5–15) 9.8±3.4 (5–15)
Body weight (kg) 34±15 (15–78) 32±12 (16–60)
Creatinine clearance (ml/min) 80±25 (30–131) 70±24 (35–128)
Creatinine clearance
(ml/min/1.73 m2)
124±35 (77–229) 110±24 (49–157)
Tobramycin peak (mg/l) 8.1±1.3 22.7±4.0
Tobramycin trough (mg/l) 0.73±0.33 0.045±0.102
Adult patients (N) 22 29
Male/female 10/12 14/15
Age (years) 22±6.3 (16–40) 24±8.4 (16–50)
Body weight (kg) 57.4±9.3 (43–82) 55.1±10.0 (31–80)
Creatinine clearance (ml/min) 93±18 (62–125) 92±20 (60–148)
Creatinine clearance
(ml/min/1.73 m2)
98±21 (63–147) 100±18 (72–150)
Tobramycin peak (mg/l) 7.9±1.4 22.6±4.6
Tobramycin trough (mg/l) 0.88±0.38 0.035±0.042
Numbers represent mean values±s.d. and range (between brackets).chlorideN60 mmol/l or a genotype known to cause the
disease). Patients were eligible if aged over 5 years and able
to participate in pulmonary-function tests reliably. Patients
were excluded if they had pre-existing hearing impairment
or renal impairment (serum creatinine concentrations
outside the reference range for the enrolling centre).
Nebulised antibiotics were discontinued on study entry.
Patients were randomly assigned to once or three times daily
tobramycin, given as a 30-min infusion in 0.9% saline
(31 ml for children, 65 ml for adults). Patients allocated to
the once daily regimen also received two infusions of 0.9%
saline per day, which was the same volume as the active
infusions to preserve the double blind study protocol. Total
daily doses equivalent to those previously received by
patients during routine treatment were used. If a patient had
not previously had tobramycin, a dose of 10 mg/kg/day was
prescribed up to a maximum of 660 mg/day. Tobramycin
concentrations were measured immediately before the fourth
infusion and 30 min after the end of the fourth infusion. All
samples were thus drawn at the same times. Target
concentrations of tobramycin for the once daily regimen
were 1 mg/l or less (trough) and 20–30 mg/l (peak); for the
three times daily regimen, these values were 2 mg/l or less
and 5–12 mg/l, respectively. If the trough concentration was
higher than the target range, the patient was withdrawn from
the study. If the peak concentration was outside the target
range, an appropriate 10% increase or 10% reduction in
dose was made as appropriate. In every case, patients
received ceftazidime as the only additional intravenous
antibiotic. Further details are given in the TOPIC paper [2].
Criteria for inclusion in the post-hoc pharmacokinetic
analysis were complete and verifiable data on drug
administration dates and times as well as accurate timings
of blood sampling and availability of tobramycin concen-
tration data.
Table 3
Tobramycin pharmacokinetic models built for paediatric and adult patients
receiving once or three times daily tobramycin and significance of
differences in pharmacokinetic parameter values
Three times daily
(N=43)
Once daily
(N=42)
p
Paediatric patients receiving tobramycin
V1 (l/kg) 0.354±0.041 0.401±0.092 0.003
Kelm (hr−1) 0.01⁎ 0.01⁎ –
Kelr (hr−1/
(ml/min/1.73 m2))
0.00291±0.00041 0.00197±0.00027 b0.001
Adult patients receiving tobramycin
3 times daily (N=22) once daily (N=29) P
V1 (l/kg) 0.295±0.060 0.305±0.050 0.16
Kelm (hr−1) 0.01⁎ 0.01⁎ –
Kelr (hr−1/
(ml/min/1.73 m2))
0.00322±0.00050 0.00252±0.00008 b0.001
V1: volume of distribution per kg body weight; Kelm: metabolic elimination
rate; Kelr: renal elimination rate per ml/min/1.73 m2 creatinine clearance;
⁎: value fixed to 0.01 because of lack of data (for explanation: see text).
Fig. 2. Relationship between renal elimination rate per ml/min/1.73 m2
creatinine clearance and age. Diamonds: paediatric patients receiving
tobramycin once daily, squares: paediatric patients receiving tobramycin
three times daily, triangles: adult patients receiving tobramycin once daily
and crosses: adult patients receiving tobramycin three times daily.
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Samples were analysed in the participating study centres
using fluorescence polarisation immuno-assays [5]. Since
different assays were used in the different participating
laboratories an overall assay error of s.d.=0.25+0.15⁎C
(where C is the concentration measured) was used in the
population pharmacokinetic analysis. Because the assay
error was taken into account, also levels that should have
been reported as below the limit of quantitation were
evaluated in the pharmacokinetic analysis.
2.3. Population pharmacokinetic analysis
At first, a single compartment open population pharma-
cokinetic model was made from all evaluable patient data.
Population modelling was performed using the MW/Pharm
pharmacokinetic software package version 3.60 [6]. InFig. 1. Relationship between volume of distribution per kg body weight and
age. Diamonds: paediatric patients receiving tobramycin once daily, squares:
paediatric patients receiving tobramycin three times daily, triangles: adult
patients receiving tobramycin once daily and crosses: adult patients
receiving tobramycin three times daily.brief: data on the patients’ gender, age, weight, height,
serum creatinine concentration, tobramycin dosages and
tobramycin serum concentrations were recorded in the
program. The pharmacokinetic equations used for the
description of tobramycin pharmacokinetics were:
V ¼ V1⁎BW
TBC ¼ V1⁎BW⁎Kel
Kel ¼ Kelmþ Kelr⁎ClCr
where:
V volume of distribution (l)
V1 volume of distribution per kg bodyweight (l/kg)
BW body weight (kg)
TBC total body clearance (l/h)
Kel elimination rate constant (h−1)
Kelm non-renal elimination rate constant (h−1)
Kelr renal elimination rate constant per ml/min creati-
nine clearance (h−1/(ml/min/1.73 m2))
ClCr estimated creatinine clearance
Creatinine clearance values were estimated using the
formula of Schwartz [7] for paediatric patients and the
formula proposed by Jelliffe [8] for adult patients. A model
previously derived from a population of CF patients was
used as starting (or prior) model [9]. Because there were no
patients included in the TOPIC study with a poor renal
function, population analysis would provide no information
on non-renal or metabolic elimination rate constant (Kelm).
Therefore, Kelm was fixed at a value of 0.01 h−1, cor-
responding with a tobramycin terminal half-life of 70 h, a
value obtained from literature [9,10].
The continuous covariates that were analysed were age,
body weight and serum creatinine concentration.
The values of the population pharmacokinetic parameters
V1 and Kelr, the intersubject variability in each parameter
and the residual error that describe the differences between
the measured and the predicted concentrations were
estimated using iterative two-stage Bayesian regression. A
330 D.J. Touw et al. / Journal of Cystic Fibrosis 6 (2007) 327–333log-normal distribution of pharmacokinetic parameter values
was assumed.
The criteria used to accept the model included the
difference in objective functions (pb0.0001 being consid-
ered to represent a significant improvement in fit), inspection
of the parameter value distribution in each cohort of patients,
convergence plots of parameter estimates and the log-
likelihood (sum of all patients analysed).
The overall pharmacokinetic model so obtained was again
used as prior model to make two new a priori models, one for
children and one for adult patients. The derived model for the
children was further used to build a model for the
subpopulation of paediatric patients receiving tobramycin
three times daily and a separate model for the subpopulation
of paediatric patients receiving tobramycin once daily. The
same was done for adults using the adult model as prior.
The mean parameter values for each cohort of patients
were used to compare the pharmacokinetic parameters of all
4 cohorts of patients and with values from the published
literature.
Individual pharmacokinetic parameter values were
obtained by fitting the appropriate a priori model for the 4
cohorts of patients to the individual data points. Individual
pharmacokinetic data points were plotted against age to
investigate this relationship.
3. Results
The TOPIC study enrolled 244 patients who were
randomised to three times daily or once daily tobramycin.
Of these, 219 patients completed the study per protocol.
More details on the results are published in the TOPIC paper
[2]. After inspection of all data of these patients, 136 patients
were eligible for inclusion in the post-hoc pharmacokinetic
analysis (43 paediatric patients on three times daily
tobramycin and 42 paediatric patients on once daily
tobramycin, 22 adult patients on three times daily tobramy-
cin and 29 adult patients on once daily tobramycin).
The characteristics of the patients included in the post-hoc
analysis are shown in Table 1. Apart from an uneven
distribution of male and female patients in the paediatric
subpopulations, the groups were comparable.
Table 2 shows the models that were built for the
population as a whole, the paediatric and adult subpopula-
tions and Table 3 shows the models stratified to the treatment
schedule and their statistics. Volume of distribution was
significantly larger in the paediatric population receiving
once daily tobramycin and Kelr was higher in the three times
daily cohorts in both the paediatric and adult populations
(Table 3).
The relationship between volume of distribution per kg
body weight and age is shown in Fig. 1 which illustrates the
significant trend, with lower values for V1 with increasing
age (non-linear regression, R2 =0.3, N=136, pb0.001).
The relationship between elimination rate per ml/min/
1.73 m2 creatinine clearance and age is shown in Fig. 2.4. Discussion
In this retrospective study we found that the volume of
distribution was significantly greater with once daily
treatment compared to three times daily in paediatric
patients. The elimination rate of tobramycin, for once
daily, was prolonged compared with three times daily dosing
in both children and adults. Further, a significant trend for a
smaller volume of distribution per kg body weight of
tobramycin with increasing age was observed.
The main strength of the present study is the large
population studied and the uniform protocol of drug
administration and data analysis.
Our study stresses again the large intersubject variability
in pharmacokinetic parameter values for tobramycin in
patients with CF. Optimal efficacy of aminoglycosides is
reached with a peak serum concentration/Minimal Inhibitory
Concentration (peak/MIC) ratio of 10. With a good total
body clearance of tobramycin, peak serum concentration
largely depends on volume of distribution. Mean volume of
distribution per kg body weight is 0.363 l/kg in paediatric
patients compared to 0.294 in adult patients (pb0.001). This
means that for the same target peak serum concentration,
paediatric patients need on average a 20% higher dose on a
mg/kg body weight basis compared to adults. Moreover, the
coefficient of variation of the volume of distribution per kg
body weight is large (22% in the paediatric population and
15% in the adult population) further adding to the wide
interindividual difference in tobramycin dosing range on a
mg/kg basis to obtain comparable target peak serum
concentration levels. Therefore, therapeutic drug monitoring
is an important tool to optimise tobramycin dose.
Together with the publication of the initial report of the
TOPIC study [2], there was debate about the correct use of a
1-compartment model for tobramycin [11,12]. It was argued
that pharmacokinetics of tobramycin administered 10 mg/kg/
day on a once daily basis is probably better described by a 2-
compartment model than a 1-compartment model [13]. In the
latter paper it was demonstrated that tobramycin volume of
distribution of the central compartment tended to be smaller
in the once daily group due to delayed distribution of the
drug [13]. It was also argued that the peak level preferably be
drawn 2 h after administration [13]. Bates [14] however,
demonstrated that tobramycin distribution is completed 1 h
after administration and based on these results a 1-h postdose
peak level was chosen in the design of the TOPIC study. In
our post-hoc pharmacokinetic analysis we found a small but
significantly larger volume of distribution of tobramycin in
the paediatric patients who received once daily tobramycin.
If a 2-compartment model was appropriate for tobramycin
then one would expect peak serum concentrations to be
relatively higher in children and adults receiving tobramycin
once daily than in the three times daily groups, as reflection
of the smaller volume of distribution in the central
compartment for the once daily group as found by
Aminimanizani [13]. Our results, however, show similar
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weight in the two adult groups and a small but significantly
higher value in the paediatric patients receiving tobramycin
once daily, contrary to what could be expected if a 2-
compartment model would describe the pharmacokinetics.
This means that at least in our population a 2-compartment
model would have had no advantages over the 1-compart-
ment model we used, providing further evidence in favour of
the design of the TOPIC study.
A higher volume of distribution is generally seen in a
younger population or may be associated with a poorer
clinical state. Our demographics show that both paediatric
populations did not differ with respect to age and body
weight. As baseline FEV1 values in the paediatric patients
receiving either once daily tobramycin or three times daily
tobramycin were comparable [2], we have no straightfor-
ward explanation for the difference in volume of distribution.
Fig. 1 of V1 against age suggests the lowering trend for V1
with increasing age. This finding is not surprising. Tobramy-
cin is like all other aminoglycosides a highly water soluble
drug that distributes mainly into extracellular fluid. With
increasing age, the relative amount of extracellular fluid tends
to decrease. This trend of decreasing volume of distribution
per kg body weight against age has also been described for
gentamicin in a non-CF paediatric population [15].
We found significantly lower mean values for Kelr in both
the paediatric and adult patient populations randomised to
once daily administration compared with the three times
daily administration. This is also depicted in Fig. 2. Kelr
must be multiplied by CrCl to result in renal elimination
constant. Creatinine clearance was estimated using the
formula of Schwartz [7] for children and Jelliffe [8] for the
adult population during the whole study and measurement of
serum creatinine concentration did not change throughout
the study. So our data suggest that the mean rate of
elimination in our population is about 30% less in the
populations who received tobramycin once daily. There are
at least four possible explanations for the observation:
Firstly it is possible that patients receiving tobramycin once
daily had more severely damaged kidneys than patients
receiving tobramycin three times daily. We feel that this is
unlikely as patients who entered the TOPIC study were
randomly allocated to the once or three times daily
administration regimen. There was no selection. Further,
renal toxicity analysis in the TOPIC study demonstrated
that at baseline mean renal function was comparable
between the once and three times daily administration
groups [2]. In our view, more renal damage in the patients
randomised to once daily therefore can be excluded.
Another possibility related to renal function is that once
daily administration of 10 mg/kg body weight of
tobramycin results in early renal damage that is not
revealed by the usual biochemical tests. Aminoglycoside
toxicity is related to dose and to the length of the therapy.
After 10–14 days of therapy, measurable signs ofnephrotoxicity appear. A rise of creatinine concentration
as marker of nephrotoxicity has been demonstrated for
adults in other diseases than CF [22,16]. However, in the
TOPIC study children who received once daily tobramycin
[2] actually had a fall in mean creatinine concentration after
14 days of treatment and so we feel that early renal damage
is unlikely to explain the prolonged Kelr seen in our
retrospective analysis.
Secondly it is possible that tobramycin clearance is sat-
urable at higher dosages. Saturable pharmacokinetics of
renally cleared drugs is not uncommon. This phenomenon
has for example also been described for piperacillin in CF
patients [17]. However, pharmacokinetic behaviour of
piperacillin and tobramycin are different. Piperacillin is
filtered by the glomerulus as well as actively excreted in the
proximal tubule, whereas tobramycin is filtered by the
glomerulus and actively reabsorbed in the tubule [18]. For
amikacin, saturation of tubular reabsorption has been
observed [18]. In other comparative studies to the phar-
macokinetics of once daily versus multiple daily ad-
ministration of tobramycin there has been no sign of
saturable pharmacokinetics [13,19].Moreover, if saturation
of reabsorption should occur, an increase of clearance
would have been observed at higher doses, which is not the
case in our study. So in our view, the observed differences in
Kelr cannot be ascribed to non-linear clearance.
A third possibility is the issue of model misspecification.
Our data were analysed by a 1-compartment model, but in
theory a 2-compartment model could also apply (see the
discussion above). On prolonged administration of
tobramycin this will lead to tissue accumulation and
redistribution from the tissues can contribute to higher
trough concentrations particularly with once daily dosing
where the trough levels are much lower (greater impact of
tissue redistribution). However, most levels were drawn at
the beginning of the tobramycin therapy when tissue
accumulation does not yet contribute to trough levels and
moreover our data were separately analysed using a 2-
compartment model. This analysis also demonstrated a
reduced value for Kelr in the once daily group, consistent
with the results obtained from the 1-compartment anal-
ysis (data not shown). Therefore, in our view, model
misspecification does not explain our findings.
Finally we considered whether the differences in
clearance observed are due to a circadian rhythm of the
clearance of the drug. This might have been influenced by
the timing of administration. After inspection of the
TOPIC data, 53 out of the 71 patients in the once daily
group received their active dose between 16.00 and
20.00 h. This means that in most patients, most of the
drug is in the body at resting time. It has been demon-
strated in animal studies that clearance of aminoglyco-
sides is significantly higher during night time, which is
the period of activity of these animals, and toxicity is
lower when these drugs are administered during the
activity period. For healthy humans, a circadian rhythm of
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ever, patient data on a circadian rhythm of drug clearance
are conflicting. In a prospective study no evidence was
found for a circadian rhythm in gentamicin pharmacoki-
netics in severely ill patients [21]. Administration of the
drug during resting time, however, did result in sig-
nificantly more nephrotoxicity [21]. On the other hand, in
endocarditis patients amikacin clearance was best de-
scribed by a model taking circadian variation of creatinine
clearance into account [22]. In CF patients who were
treated with a continuous infusion of ceftazidime, a cir-
cadian rhythm for ceftazidime clearance was observed
with a reduced clearance during resting hours [23]. Other
investigators found a lower total body clearance for
aminoglycosides during the resting period [24–26] or no
difference [27]. These conflicting results may be caused
by the nature of the patients studied. From animal studies
it is clear that there are circadian differences related to
night time and daytime, or, in other words, to activity and
rest. In patient studies, night time and daytime are not
always similar to rest and activity. Studies that included
severely ill patients [21,27] found no differences in
aminoglycoside pharmacokinetics between daytime and
night time, whereas studies with CF patients [23] and
freely ambulating patients [24] did. Since CF patients are
encouraged to exercise during daytime and, if treated at
home, to resume their normal life, there is considerable
activity at daytime. Further, it is interesting to note that
Bleyzac et al. [25], who used the same type of population
analysis as we performed, found a difference in
elimination rate in the same order of magnitude for
evening dosing versus morning dosing as we observed for
once daily versus three times daily dosing. Another factor
of influence on aminoglycoside clearance may be the
dietary intake of proteins [28].Thus, our observation of a
lower Kelr for both paediatric and adult once daily groups
may be the result of a circadian rhythm in drug clearance
caused by either activity and rest or dietary protein intake
or both combined with the administration of the active
dose in the once daily group in the early evening.
In conclusion, we observed a significant difference in
elimination constant with a 30% lower value for patients
receiving the active dose of tobramycin once daily in the
evening. This observation may be the result of a circadian
rhythm in drug clearance as observed in other studies. A
further possibility (which is not supported by the data from the
TOPIC study) is a previously unknown aspect of aminoglyco-
side toxicity, with early renal toxicity at high dosages, not
revealed by routine biochemistry measurements. We hope to
study this in a trial that randomises patients on once daily
tobramycin to 0800 h, 1600 h or 2400 h administration and
studies the Kelr, creatinine and NAG concentrations. Until
these results are available we would suggest that once daily
tobramycin be administered in the morning. Further, the
population pharmacokinetic models, provided by our studycan be used to develop dosing schemes for predetermined
tobramycin target peak and trough concentrations in CF
patients. Because of the wide interindividual range of volume
of distribution and hence in required dose for predetermined
optimal serum concentrations to avoid underdosing on the one
hand and too high serum concentrations on the other hand,
monitoring of serum concentrations remains necessary.
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